EP3004877 - COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT PREVENTION, AND TREATMENT OF CANCER USING PD-L1 ISOFORMS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 03.08.2018 Database last updated on 24.08.2024 | |
Former | Examination is in progress Status updated on 10.11.2017 | Most recent event Tooltip | 03.08.2018 | Application deemed to be withdrawn | published on 05.09.2018 [2018/36] | Applicant(s) | For all designated states Dana-Farber Cancer Institute, Inc. 450 Brookline Avenue Boston MA 02459 / US | [2016/15] | Inventor(s) | 01 /
HAMMERMAN, Peter 217 Greenwood Street Newton, MA 02459 / US | [2016/15] | Representative(s) | Helbig, Christian Wagner + Helbig Patentanwälte Pfarrstrasse 14 80538 München / DE | [2016/15] | Application number, filing date | 14807512.0 | 02.06.2014 | [2016/15] | WO2014US40504 | Priority number, date | US201361831894P | 06.06.2013 Original published format: US 201361831894 P | [2016/15] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2014197369 | Date: | 11.12.2014 | Language: | EN | [2014/50] | Type: | A1 Application with search report | No.: | EP3004877 | Date: | 13.04.2016 | Language: | EN | The application published by WIPO in one of the EPO official languages on 11.12.2014 takes the place of the publication of the European patent application. | [2016/15] | Search report(s) | International search report - published on: | US | 11.12.2014 | (Supplementary) European search report - dispatched on: | EP | 17.03.2017 | Classification | IPC: | G01N33/50, C12Q1/68 | [2017/02] | CPC: |
C12Q1/6886 (EP,US);
A61P35/00 (EP);
G01N33/57407 (EP,US);
G01N33/57423 (EP,US);
G01N33/57492 (US);
C12N15/1138 (US);
C12N2310/11 (US);
C12N2320/30 (US);
C12Q2600/106 (EP,US);
C12Q2600/112 (EP,US);
C12Q2600/118 (EP,US);
C12Q2600/156 (EP,US);
C12Q2600/158 (EP,US);
G01N2333/4703 (US);
G01N2333/70503 (US);
G01N2333/70596 (EP,US);
G01N2500/00 (EP,US);
G01N2500/04 (US);
|
Former IPC [2016/15] | G01N33/50 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2016/15] | Title | German: | ZUSAMMENSETZUNGEN UND VERFAHREN ZUR IDENTIFIKATION, BEURTEILUNG, VORBEUGUNG UND BEHANDLUNG VON KREBS MIT PD-L1-ISOFORMEN | [2016/15] | English: | COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT PREVENTION, AND TREATMENT OF CANCER USING PD-L1 ISOFORMS | [2016/15] | French: | COMPOSITIONS ET PROCÉDÉS D'IDENTIFICATION, D'ÉVALUATION, DE PRÉVENTION ET DE TRAITEMENT DU CANCER EN UTILISANT DES ISOFORMES PD-L1 | [2016/15] | Entry into regional phase | 04.01.2016 | National basic fee paid | 04.01.2016 | Search fee paid | 04.01.2016 | Designation fee(s) paid | 04.01.2016 | Examination fee paid | Examination procedure | 04.01.2016 | Examination requested [2016/15] | 13.10.2017 | Amendment by applicant (claims and/or description) | 14.11.2017 | Despatch of a communication from the examining division (Time limit: M04) | 27.03.2018 | Application deemed to be withdrawn, date of legal effect [2018/36] | 25.04.2018 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2018/36] | Divisional application(s) | EP17197526.1 / EP3293275 | Fees paid | Renewal fee | 27.06.2016 | Renewal fee patent year 03 | 27.06.2017 | Renewal fee patent year 04 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XI] - YAN ZHANG ET AL, "Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer", CELLULAR & MOLECULAR IMMUNOLOGY, CH, (20100531), vol. 7, no. 5, doi:10.1038/cmi.2010.28, ISSN 1672-7681, pages 389 - 395, XP055326497 [X] 9,11,12 * abstract * * Results, first section.;; figure 1 * [I] 1-8,10,13-15 DOI: http://dx.doi.org/10.1038/cmi.2010.28 | [XI] - S. LYFORD-PIKE ET AL, "Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma", CANCER RESEARCH, (20130103), vol. 73, no. 6, doi:10.1158/0008-5472.CAN-12-2384, ISSN 0008-5472, pages 1733 - 1741, XP055179352 [X] 9,11,12 * abstract * * page 1736; figure 2 * [I] 1-8,10,13-15 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-12-2384 | [XI] - SARA I. PAI, "Adaptive immune resistance in HPV-associated head and neck squamous cell carcinoma", ONCOIMMUNOLOGY, (20130501), vol. 2, no. 5, doi:10.4161/onci.24065, page e24065, XP055326362 [X] 9,11,12 * page e24065, column 2, paragraph 1 * [I] 1-8,10,13-15 DOI: http://dx.doi.org/10.4161/onci.24065 | [XI] - C. BADOUAL ET AL, "PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer", CANCER RESEARCH, US, (20121107), vol. 73, no. 1, doi:10.1158/0008-5472.CAN-12-2606, ISSN 0008-5472, pages 128 - 138, XP055326633 [X] 9,11,12 * abstract * [I] 1-8,10,13-15 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-12-2606 | [XI] - Suzanne L Topalian ET AL, "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", The New England journal of medicine, United States, doi:10.1056/NEJMoa1200690, (20120628), pages 2443 - 2454, URL: http://search.proquest.com/docview/1022620071, XP055098235 [X] 9,11,12 * abstract * [I] 1-8,10,13-15 DOI: http://dx.doi.org/10.1056/NEJMoa1200690 | International search | [X]US2011033884 (WOOD CLIVE [US], et al) [X] 1-60 * entire document *; | [A]WO2011049603 (DANA FARBER CANCER INST INC [US], et al) [A] 1-60 * entire document *; | [A]US2011271358 (FREEMAN GORDON J [US], et al) [A] 1-60 * ) entire document *; | [A]US2012237522 (KANG CHANG YUIL [KR], et al) [A] 1-60 * entire document *; | [A] - GRZYWNOWICZ et al., "Programmed Death-1 and Its Ligand Are Novel Immunotolerant Molecules Expressed on Leukemic B Cells in Chronic Lymphocytic Leukemia", PLoS One, vol. 7, no. Iss. 4, pages 1 - 7, XP055300125 [A] 1-60 * . entire document * DOI: http://dx.doi.org/10.1371/journal.pone.0035178 |